419 related articles for article (PubMed ID: 32871345)
1. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Tomaselli D; Mautone N; Mai A; Rotili D
Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Vogelmann A; Robaa D; Sippl W; Jung M
Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
4. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
Liang Y; Nandakumar KS; Cheng K
Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
[TBL] [Abstract][Full Text] [Related]
5. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
6. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
Wang C; Zhang Y; Xing D; Zhang R
Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
8. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
9. Targeted protein degradation: elements of PROTAC design.
Paiva SL; Crews CM
Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
11. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
Wang C; Zhang Y; Wang J; Xing D
Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
[TBL] [Abstract][Full Text] [Related]
12. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
13. The Present and Future of Novel Protein Degradation Technology.
Xia L; Liu W; Song Y; Zhu H; Duan Y
Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
15. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).
Tomoshige S; Ishikawa M
Bioorg Med Chem; 2021 Jul; 41():116221. PubMed ID: 34034148
[TBL] [Abstract][Full Text] [Related]
16. PROTACs- a game-changing technology.
Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
[No Abstract] [Full Text] [Related]
17. Assays and technologies for developing proteolysis targeting chimera degraders.
Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
19. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
